Splanchnic vein thrombosis in patients with COVID-19 infection

Apr 6, 2021

The novel coronavirus pandemic leads to rapid dissemination around the world. COVID-19 has been causing death primarily due to pneumonia and respiratory failure. One of the complications which has been described in COVID-19 infection is the increased systemic inflammatory response from the virus which leads to a higher risk of hypercoagulability and associated thromboembolic disease [1, 2].
Splanchnic vein thrombosis occurring outside the setting of cirrhosis is a rare condition which is thought to account for 5% to 10% of all patients with portal hypertension in developed countries [3]. It can be associated with severe complications such as gastrointestinal bleeding, portal biliopathy, and intestinal ischemia [4, 5]. Currently, only a few cases of splanchnic vein thrombosis have been reported in patients with COVID-19 [6]. Considering the high risk of thrombotic events in patients with COVID-19 infection, the burden of splanchnic vein thrombosis should be assessed in a large series of patients.

Project recruiting

Aims

  • To assess the burden of splanchnic vein thrombosis in patients with COVID-19 infection
  • To evaluate which splanchnic vein (hepatic, portal, mesenteric, splenic veins) are at risk of thrombosis during COVID-19 infection
  • To assess the prevalence of other prothrombotic conditions than the hypercoagulable state induced by COVID-19
  • To assess the impact of splanchnic vein thrombosis on the prognosis of patients with COVID-19 infection
  • To assess the prognosis factors associated with poor outcome
  • To assess the rate of recanalization without or under anticoagulation therapy

Study file(s)

Contact(s)

You must be member of Valdig to access files and contact details.